17 Jul 2019

SENATE BILL TO CUT SURPRISE MEDICAL BILLS AND DRUG PRICES WOULD SAVE U.S. $7 BILLION

The nonpartisan Congressional Budget Office (CBO) says that Senate bill 1895 to tackle surprise medical bills and high drug prices would save the federal government about $7 billion over the next 10 years. The estimate released Tuesday could help the package’s chances for passage through the Senate by easing concerns over the impact

0
12 Jul 2019

PAYER ANALYSIS: ‘CADILLAC TAX’ ON HIGH-COST HEALTH PLANS COULD AFFECT 1 IN 5 EMPLOYERS IN 2022

[/infobox]   A new KFF analysis estimates that the Affordable Care Act’s tax on high-cost health plans would affect one in five (21 percent) employers offering health benefits when it takes effect in 2022 unless employers change their health plans. An even larger share (31 percent) could be affected when workers’ voluntary

0
26 Jun 2019

VIVA AND THE VEINS 2019: Dr. Suresh Vedantham to receive VEIN Award; abstracts now being accepted

Suresh Vedantham, MD, past president of the Society of Interventional Radiology, will receive the 2019 Venous Educator, Innovator, and National Statesman Award (VEIN AWARD) during VIVA and The VEINS2019 conference Nov. 4-7 at the Wynn Las Vegas. Dr. Vedantham is a professor of Radiology & Surgery at the Mallinckrodt Institute of Radiology at the

0
26 Jun 2019

 ANGIODYNAMICS SELLS NAMIC fluid management portfolio

AngioDynamics Inc., a provider of innovative, minimally invasive medical devices for oncology, vascular access and peripheral vascular disease, has agreed to sell its NAMIC fluid management portfolio to Medline Industries Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The

0
26 Jun 2019

F:LIP/FOCUS: LIVE, INTERACTIVE, PRACTICAL:AVLS OPENS REGISTRATION FOR 33RD ANNUAL CONGRESS NOV. 7-10 IN PHOENIX

By Larry Storer Online registration for the American Vein and Lymphatic Society’s 33rd Annual Congress, Nov. 7-10 at the JW Marriott Desert Ridge Resort and Spa in Phoenix, opened May 6 at avlscongress.org. “Early in 2018, Elsevier reported that medical knowledge was doubling every few months, posing serious challenges to

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0
26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0
12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0
12 Jun 2019

MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly

0